Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial.

Strezova A, Lal H, Enweonye I, Campora L, Beukelaers P, Segall N, Heineman TC, Schuind AE, Oostvogels L.

Vaccine. 2019 Sep 16;37(39):5877-5885. doi: 10.1016/j.vaccine.2019.08.001. Epub 2019 Aug 20.

2.

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.

Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, Sohn SK, Rodriguez Macías G, Chiou TJ, Quiel D, Aoun M, Navarro Matilla MB, de la Serna J, Milliken S, Murphy J, McNeil SA, Salaun B, Di Paolo E, Campora L, López-Fauqued M, El Idrissi M, Schuind A, Heineman TC, Van den Steen P, Oostvogels L; Zoster-039 study group.

Lancet Infect Dis. 2019 Sep;19(9):988-1000. doi: 10.1016/S1473-3099(19)30163-X. Epub 2019 Aug 6.

PMID:
31399377
3.

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.

Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, Gaidano G, Lee JJ, Abhyankar S, Solano C, Perez de Oteyza J, Satlin MJ, Schwartz S, Campins M, Rocci A, Vallejo Llamas C, Lee DG, Tan SM, Johnston AM, Grigg A, Boeckh MJ, Campora L, Lopez-Fauqued M, Heineman TC, Stadtmauer EA, Sullivan KM; ZOE-HSCT Study Group Collaborators.

JAMA. 2019 Jul 9;322(2):123-133. doi: 10.1001/jama.2019.9053. Erratum in: JAMA. 2019 Aug 27;322(8):785.

PMID:
31287523
4.

Workforce analysis of practicing rhinologists in the united states.

Heineman TE, Ramakrishnan V, Hwang PH, Suh JD.

Laryngoscope. 2019 Jun 27. doi: 10.1002/lary.28157. [Epub ahead of print]

PMID:
31246279
5.

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials.

Oostvogels L, Heineman TC, Johnson RW, Levin MJ, McElhaney JE, Van den Steen P, Zahaf T, Dagnew AF, Chlibek R, Diez-Domingo J, Gorfinkel IS, Hervé C, Hwang SJ, Ikematsu H, Kalema G, Lal H, McNeil SA, Mrkvan T, Pauksens K, Smetana J, Watanabe D, Weckx LY, Cunningham AL.

Hum Vaccin Immunother. 2019 Jun 28:1-8. doi: 10.1080/21645515.2019.1627818. [Epub ahead of print]

PMID:
31216205
6.

Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease.

Bernstein DI, Flechtner JB, McNeil LK, Heineman T, Oliphant T, Tasker S, Wald A, Hetherington S; Genocea study group.

Vaccine. 2019 Jun 6;37(26):3443-3450. doi: 10.1016/j.vaccine.2019.05.009. Epub 2019 May 15.

PMID:
31103365
7.

Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine.

Heineman TC, Cunningham A, Levin M.

Curr Opin Immunol. 2019 Aug;59:42-48. doi: 10.1016/j.coi.2019.02.009. Epub 2019 Apr 17. Review.

PMID:
31003070
8.

Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.

López-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, Diez-Domingo J, Heineman TC, Lal H, McElhaney JE, McNeil SA, Yeo W, Tavares-Da-Silva F; ZOE-50/70 Study Group.

Vaccine. 2019 Apr 24;37(18):2482-2493. doi: 10.1016/j.vaccine.2019.03.043. Epub 2019 Mar 29.

9.

Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: a Phase III, Randomized Clinical Trial.

Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim SJ, Kim SI, Zaltzman J, Ortiz F, Campistol Plana JM, Fernandez Rodriguez AM, Rebollo Rodrigo H, Campins Marti M, Perez R, González Roncero FM, Kumar D, Chiang YJ, Doucette K, Pipeleers L, Agüera Morales ML, Rodriguez-Ferrero ML, Secchi A, McNeil SA, Campora L, Di Paolo E, El Idrissi M, López-Fauqued M, Salaun B, Heineman T, Oostvogels L; Z-041 study group.

Clin Infect Dis. 2019 Mar 7. pii: ciz177. doi: 10.1093/cid/ciz177. [Epub ahead of print]

PMID:
30843046
10.

Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial' [Vaccine 36 (2018) 4278-4286].

Maréchal C, Lal H, Poder A, Ferguson M, Enweonye I, Heineman TC, Hervé C, Rheault P, Talli J, Wauters D, Oostvogels L.

Vaccine. 2019 Feb 21;37(9):1252-1253. doi: 10.1016/j.vaccine.2019.01.022. Epub 2019 Jan 30. No abstract available.

11.

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial.

Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, Grande E, Marrupe Gonzalez D, Lowndes S, Puente J, Kristeleit H, Farrugia D, McNeil SA, Campora L, Di Paolo E, El Idrissi M, Godeaux O, López-Fauqued M, Salaun B, Heineman TC, Oostvogels L; Zoster-028 Study Group.

Cancer. 2019 Apr 15;125(8):1301-1312. doi: 10.1002/cncr.31909. Epub 2019 Feb 1.

12.

Oral tongue squamous cell carcinoma survival as stratified by age and sex: A surveillance, epidemiology, and end results analysis.

Mukdad L, Heineman TE, Alonso J, Badran KW, Kuan EC, St John MA.

Laryngoscope. 2019 Sep;129(9):2076-2081. doi: 10.1002/lary.27720. Epub 2018 Dec 21.

PMID:
30575045
13.

Quality of Life impact of a Recombinant Zoster Vaccine in adults ≥50 Years of Age.

Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Lal H, Andrews C, Athan E, Berglund J, Campora L, de Looze F, Korhonen T, Leung E, Levin M, Volpi A, Johnson RW; ZOE-50/70 study group.

J Gerontol A Biol Sci Med Sci. 2018 Jun 27. doi: 10.1093/gerona/gly150. [Epub ahead of print]

14.

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial.

Maréchal C, Lal H, Poder A, Ferguson M, Enweonye I, Heineman TC, Hervé C, Rheault P, Talli J, Wauters D, Oostvogels L.

Vaccine. 2018 Jul 5;36(29):4278-4286. doi: 10.1016/j.vaccine.2018.05.110. Epub 2018 Jun 11. Erratum in: Vaccine. 2019 Feb 21;37(9):1252-1253.

15.

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.

Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang SJ, McElhaney JE, Vesikari T, Andrews C, Choi WS, Esen M, Ikematsu H, Choma MK, Pauksens K, Ravault S, Salaun B, Schwarz TF, Smetana J, Abeele CV, Van den Steen P, Vastiau I, Weckx LY, Levin MJ; ZOE-50/70 Study Group.

J Infect Dis. 2018 May 5;217(11):1750-1760. doi: 10.1093/infdis/jiy095.

16.

Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials.

Kovac M, Lal H, Cunningham AL, Levin MJ, Johnson RW, Campora L, Volpi A, Heineman TC; ZOE-50/70 Study Group.

Vaccine. 2018 Mar 14;36(12):1537-1541. doi: 10.1016/j.vaccine.2018.02.029. Epub 2018 Feb 17.

17.

Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults.

Schwarz TF, Volpe S, Catteau G, Chlibek R, David MP, Richardus JH, Lal H, Oostvogels L, Pauksens K, Ravault S, Rombo L, Sonder G, Smetana J, Heineman T, Bastidas A.

Hum Vaccin Immunother. 2018 Jun 3;14(6):1370-1377. doi: 10.1080/21645515.2018.1442162. Epub 2018 Mar 21.

18.

Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.

Lal H, Poder A, Campora L, Geeraerts B, Oostvogels L, Vanden Abeele C, Heineman TC.

Vaccine. 2018 Jan 2;36(1):148-154. doi: 10.1016/j.vaccine.2017.11.019. Epub 2017 Nov 22.

19.

Is multidisciplinary team care for head and neck cancer worth it?

Badran KW, Heineman TE, Kuan EC, St John MA.

Laryngoscope. 2018 Jun;128(6):1257-1258. doi: 10.1002/lary.26919. Epub 2017 Nov 6. No abstract available.

PMID:
29105775
20.

A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.

Strezova A, Godeaux O, Aggarwal N, Leroux-Roels G, Lopez-Fauqued M, Van Damme P, Vanden Abeele C, Vastiau I, Heineman TC, Lal H.

Vaccine. 2017 Dec 4;35(48 Pt B):6700-6706. doi: 10.1016/j.vaccine.2017.10.017. Epub 2017 Oct 24.

21.

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.

Schwarz TF, Aggarwal N, Moeckesch B, Schenkenberger I, Claeys C, Douha M, Godeaux O, Grupping K, Heineman TC, Fauqued ML, Oostvogels L, Van den Steen P, Lal H.

J Infect Dis. 2017 Dec 12;216(11):1352-1361. doi: 10.1093/infdis/jix481.

22.

Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.

Grupping K, Campora L, Douha M, Heineman TC, Klein NP, Lal H, Peterson J, Vastiau I, Oostvogels L.

J Infect Dis. 2017 Dec 12;216(11):1343-1351. doi: 10.1093/infdis/jix482.

23.

The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer.

Heineman TE, Widman A, Kuan EC, St John M.

Laryngoscope Investig Otolaryngol. 2017 May 17;2(3):99-103. doi: 10.1002/lio2.79. eCollection 2017 Jun.

24.

It Takes a Village: The Importance of Multidisciplinary Care.

Heineman T, St John MA, Wein RO, Weber RS.

Otolaryngol Clin North Am. 2017 Aug;50(4):679-687. doi: 10.1016/j.otc.2017.03.005. Epub 2017 Jun 9. Review.

PMID:
28606602
25.

Vaccine profile of herpes zoster (HZ/su) subunit vaccine.

Cunningham AL, Heineman T.

Expert Rev Vaccines. 2017 Jul;16(7):1-10. doi: 10.1080/14760584.2017.1329012. Epub 2017 May 19. Review.

PMID:
28486850
26.

Anatomic Variations in Pituitary Endocrinopathies: Implications for the Surgical Corridor.

Kuan EC, Yoo F, Kim W, Badran KW, Heineman TE, Sepahdari AR, Bergsneider M, Wang MB.

J Neurol Surg B Skull Base. 2017 Apr;78(2):105-111. doi: 10.1055/s-0036-1585588. Epub 2016 Aug 10.

27.

When should surveillance imaging be performed after treatment for head and neck cancer?

Heineman TE, Kuan EC, St John MA.

Laryngoscope. 2017 Mar;127(3):533-534. doi: 10.1002/lary.26268. Epub 2017 Feb 10. Review. No abstract available.

PMID:
28185273
28.

Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.

Godeaux O, Kovac M, Shu D, Grupping K, Campora L, Douha M, Heineman TC, Lal H.

Hum Vaccin Immunother. 2017 May 4;13(5):1051-1058. doi: 10.1080/21645515.2016.1265715. Epub 2017 Jan 9.

29.

Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly.

Vink P, Shiramoto M, Ogawa M, Eda M, Douha M, Heineman T, Lal H.

Hum Vaccin Immunother. 2017 Mar 4;13(3):574-578. doi: 10.1080/21645515.2016.1232787. Epub 2016 Dec 9.

30.

Should adult surgical tracheostomies include a Bjork flap?

Au JK, Heineman TE, Schmalbach CE, St John MA.

Laryngoscope. 2017 Mar;127(3):535-536. doi: 10.1002/lary.26305. Epub 2016 Sep 19. Review. No abstract available.

31.

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group.

N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800.

32.

Multiple endocrine neoplasia type 2 kindred with novel tandem RET mutations: Case report with an applied in silico mutational tolerance analysis.

Joshi RR, Heineman TE, Kutler DI, Cohen MA, Kuhel WI.

Head Neck. 2016 Apr;38 Suppl 1:E1881-5. doi: 10.1002/hed.24340. Epub 2016 Feb 15.

PMID:
26876062
33.

Response to "Parathyroid Surgery: Getting It Right the First Time": Parathyroid Surgery: Primum Non Nocere.

Kuhel WI, Kutler DI, Cohen M, Heineman T.

Otolaryngol Head Neck Surg. 2016 Feb;154(2):397. doi: 10.1177/0194599815619602. No abstract available.

PMID:
26833648
34.

Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

Lal H, Cunningham AL, Heineman TC.

N Engl J Med. 2015 Oct 15;373(16):1576-7. doi: 10.1056/NEJMc1508392. No abstract available.

PMID:
26465999
35.

Dimensions and Anatomical Variants of the Foramen Transversarium of Typical Cervical Vertebrae.

Sangari SK, Dossous PM, Heineman T, Mtui EP.

Anat Res Int. 2015;2015:391823. doi: 10.1155/2015/391823. Epub 2015 Sep 10.

36.

Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults.

Chlibek R, Pauksens K, Rombo L, van Rijckevorsel G, Richardus JH, Plassmann G, Schwarz TF, Catteau G, Lal H, Heineman TC.

Vaccine. 2016 Feb 3;34(6):863-8. doi: 10.1016/j.vaccine.2015.09.073. Epub 2015 Oct 1.

37.

Idiopathic Chronic Parotitis: Imaging Findings and Sialendoscopic Response.

Heineman TE, Kacker A, Kutler DI.

ORL J Otorhinolaryngol Relat Spec. 2015;77(5):302-9. doi: 10.1159/000438760. Epub 2015 Sep 17.

PMID:
26376430
38.

Is Intraoperative Parathyroid Hormone Monitoring Warranted in Cases of 4D-CT/Ultrasound Localized Single Adenomas?

Heineman TE, Kutler DI, Cohen MA, Kuhel WI.

Otolaryngol Head Neck Surg. 2015 Aug;153(2):183-8. doi: 10.1177/0194599815590597. Epub 2015 Jun 29.

PMID:
26124265
39.

In Silico Analysis of NF2 Gene Missense Mutations in Neurofibromatosis Type 2: From Genotype to Phenotype.

Heineman TE, Evans DG, Campagne F, Selesnick SH.

Otol Neurotol. 2015 Jun;36(5):908-14. doi: 10.1097/MAO.0000000000000639.

PMID:
25931164
40.

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC; ZOE-50 Study Group.

N Engl J Med. 2015 May 28;372(22):2087-96. doi: 10.1056/NEJMoa1501184. Epub 2015 Apr 28.

41.

Parathyroid Localization and Preservation during Transcervical Resection of Substernal Thyroid Glands.

Heineman TE, Kadkade P, Kutler DI, Cohen MA, Kuhel WI.

Otolaryngol Head Neck Surg. 2015 Jun;152(6):1024-8. doi: 10.1177/0194599815578105. Epub 2015 Apr 6.

PMID:
25847147
42.

In silico analysis of RET variants in medullary thyroid cancer: from the computer to the bedside.

Heineman TE, Joshi R, Cohen MA, Kuhel WI, Kutler DI.

Otolaryngol Head Neck Surg. 2015 Apr;152(4):650-4. doi: 10.1177/0194599815569709. Epub 2015 Mar 2.

PMID:
25733075
43.

Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.

Berkowitz EM, Moyle G, Stellbrink HJ, Schürmann D, Kegg S, Stoll M, El Idrissi M, Oostvogels L, Heineman TC; Zoster-015 HZ/su Study Group.

J Infect Dis. 2015 Apr 15;211(8):1279-87. doi: 10.1093/infdis/jiu606. Epub 2014 Nov 3.

44.

A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.

Stadtmauer EA, Sullivan KM, Marty FM, Dadwal SS, Papanicolaou GA, Shea TC, Mossad SB, Andreadis C, Young JA, Buadi FK, El Idrissi M, Heineman TC, Berkowitz EM.

Blood. 2014 Nov 6;124(19):2921-9. doi: 10.1182/blood-2014-04-573048. Epub 2014 Sep 18.

45.

HSV-1 and HSV-2 seroprevalence in the united states among asymptomatic women unaware of any herpes simplex virus infection (Herpevac Trial for Women).

Schulte JM, Bellamy AR, Hook EW 3rd, Bernstein DI, Levin MJ, Leone PA, Sokol-Anderson ML, Ewell MG, Wolff PA, Heineman TC, Belshe RB.

South Med J. 2014 Feb;107(2):79-84. doi: 10.1097/SMJ.0000000000000062.

PMID:
24926671
46.

Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study.

Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, Plassmann G, Schwarz TF, Ledent E, Heineman TC.

Vaccine. 2014 Mar 26;32(15):1745-53. doi: 10.1016/j.vaccine.2014.01.019. Epub 2014 Feb 6.

PMID:
24508036
47.

Factors predictive of voice and swallowing outcomes after anterior approaches to the cervical spine.

Mehra S, Heineman TE, Cammisa FP Jr, Girardi FP, Sama AA, Kutler DI.

Otolaryngol Head Neck Surg. 2014 Feb;150(2):259-65. doi: 10.1177/0194599813515414. Epub 2013 Dec 23.

PMID:
24367048
48.

Correlate of immune protection against HSV-1 genital disease in vaccinated women.

Belshe RB, Heineman TC, Bernstein DI, Bellamy AR, Ewell M, van der Most R, Deal CD.

J Infect Dis. 2014 Mar;209(6):828-36. doi: 10.1093/infdis/jit651. Epub 2013 Nov 27.

49.

Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial.

Gorfinkel IS, Aoki F, McNeil S, Dionne M, Shafran SD, Zickler P, Halperin S, Langley J, Bellamy A, Schulte J, Heineman T, Belshe R.

Int J STD AIDS. 2013 May;24(5):345-9. doi: 10.1177/0956462412472822.

PMID:
23970700
50.

Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age.

Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, Heineman TC.

J Infect Dis. 2013 Dec 15;208(12):1953-61. doi: 10.1093/infdis/jit365. Epub 2013 Jul 31.

PMID:
23904292

Supplemental Content

Loading ...
Support Center